Related Experiment Video
Updated: Dec 29, 2025
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Atherosclerosis and beta-blockade: A forgotten option?
Insights
Beta-blockers show varied benefits in hypertension management. While less effective than other treatments for uncomplicated cases, their specific properties may offer cardiovascular protection, particularly in patients with existing conditions.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Beta-blockers are currently ranked fourth for arterial hypertension management.
- This ranking is influenced by studies showing lesser benefits compared to other antihypertensive therapies.
- Differences among beta-blockers, including selectivity and metabolic effects, impact their clinical utility.
Purpose of the Study:
- To re-evaluate the role of beta-blockers in cardiovascular prevention.
- To investigate the metabolic properties and potential antiatherogenic actions of beta-blockers.
- To determine the appropriate place for beta-blockers in treating hypertension and preventing cardiovascular events.
Main Methods:
- Review of clinical trial data comparing different antihypertensive strategies.
- Analysis of studies focusing on beta-blocker properties like receptor selectivity, lipophilicity, and metabolic effects.
- Examination of evidence regarding beta-blockers in patients with atherothrombotic events and heart failure.
- Assessment of effects on atherosclerosis, lipid profiles, vascular wall quality, and inflammation.
Main Results:
- Beta-blockers demonstrate varying efficacy, with some showing less benefit than control therapies in uncomplicated hypertension.
- Specific beta-blocker properties significantly influence therapeutic outcomes.
- Evidence supports beta-blocker use in patients with a history of atherothrombotic events or heart failure.
- Concerns exist regarding unfavorable metabolic side effects, particularly insulin resistance, in patients with dyslipidemia, diabetes, or obesity.
Conclusions:
- The clinical utility of beta-blockers is highly dependent on the specific agent and patient profile.
- Further research into the metabolic and antiatherogenic properties of beta-blockers is warranted.
- Careful consideration of metabolic profiles is crucial when prescribing beta-blockers, especially for at-risk populations.
Abstract:
Beta-blockers have been ranked fourth in management recommendations for arterial hypertension in the management of arterial hypertension. This “retreat” is justified by the results of studies comparing different antihypertensive strategies that documented a lesser benefit of the beta-blockers tested compared to control therapies. Obviously, even within the beta-adrenergic receptor blocking group, there are important differences between agents. Properties such as selectivity to receptors and their subtypes, hydrophilicity and resp. lipophilicity, control of blood pressure, influence of intermediate metabolism or directly influence on vascular reactivity determine the resulting potential benefit associated with therapy. The results of clinical trials are also influenced by the test population and concomitant medications. There are a number of studies documenting the benefit of beta-blockers in patients with a history of atherothrombotic events or in the context of heart failure. In the context of the treatment of (yet) uncomplicated hypertension, we are interested not only in the main effects - lowering blood pressure, but also in other potentially effects significant for the resulting effect and influencing the prognosis (favorable or undesirable). In the case of beta-blockers, the effect on atherosclerosis development, lipidogram, vascular wall quality, anti-inflammatory effects, etc. In beta-blockers, several studies have suggested that their metabolic side-effect profile is so unfavorable that they need insulin resistance in patients with dyslipidemia, diabetes or obesity always avoid. This article returns to the question of the metabolic properties of beta-blockers and their possible direct antiatherogenic action and thus the site that this drug class should have in the field of cardiovascular prevention.
Related Concept Videos
01:26Atherosclerosis III: Management
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:22Heart Failure Drugs: β-Blockers
01:23Atherosclerosis IV: Nursing Management